Review
doi: 10.3109/09540261.2013.776522.
From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers
Affiliations
- PMID: 23611350
- DOI: 10.3109/09540261.2013.776522
Item in Clipboard
Review
From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers
Int Rev Psychiatry.
2013 Apr.
Abstract
Frontotemporal dementia (FTD) is an increasingly recognized cause of dementia. This review discusses the different FTD clinical syndromes and frontotemporal lobar degeneration (FTLD) pathological correlates as well as new genetic and proteomic findings that have added to our understanding of FTLD pathogenesis. Various diagnostic modalities including the use of biomarkers will also be addressed. Finally we will highlight future directions in the FTD field. More research is needed to elucidate the cellular mechanisms of neurodegeneration in FTLD and improve clinical diagnostic capabilities.
Similar articles
-
Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation.Acta Neuropathol. 2005 Nov;110(5):501-12. doi: 10.1007/s00401-005-1079-4. Epub 2005 Oct 13. Acta Neuropathol. 2005. PMID: 16222525
-
Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI.Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):242-7. doi: 10.1097/WAD.0b013e3181cfe326. Alzheimer Dis Assoc Disord. 2010. PMID: 20683185
-
The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.Brain. 2011 Sep;134(Pt 9):2478-92. doi: 10.1093/brain/awr189. Epub 2011 Aug 11. Brain. 2011. PMID: 21840888
-
[The diagnosis of frontotemporal dementia].Fortschr Neurol Psychiatr. 2002 May;70(5):243-51. doi: 10.1055/s-2002-28432. Fortschr Neurol Psychiatr. 2002. PMID: 12007075 Review. German.
-
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.J Neurochem. 2016 Aug;138 Suppl 1:184-92. doi: 10.1111/jnc.13669. Epub 2016 Jun 15. J Neurochem. 2016. PMID: 27186717 Review.
Cited by
-
CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.Neurology. 2018 Jan 9;90(2):e157-e163. doi: 10.1212/WNL.0000000000004799. Epub 2017 Dec 13. Neurology. 2018. PMID: 29237796 Free PMC article.
-
Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.Sci Rep. 2021 May 25;11(1):10837. doi: 10.1038/s41598-021-90366-5. Sci Rep. 2021. PMID: 34035398 Free PMC article.
-
Current Status of Clinical Trials on Tau Immunotherapies.Drugs. 2021 Jul;81(10):1135-1152. doi: 10.1007/s40265-021-01546-6. Epub 2021 Jun 8. Drugs. 2021. PMID: 34101156 Free PMC article. Review.
-
Antibody-derived in vivo imaging of tau pathology.J Neurosci. 2014 Dec 10;34(50):16835-50. doi: 10.1523/JNEUROSCI.2755-14.2014. J Neurosci. 2014. PMID: 25505335 Free PMC article.
-
Tau immunotherapies: Lessons learned, current status and future considerations.Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28. Neuropharmacology. 2020. PMID: 32360477 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
